TherapeuticsMD
TXMD
44 hedge funds and large institutions have $5.52M invested in TherapeuticsMD in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 6 closing their positions.
56% more capital invested
Capital invested by funds: $3.54M → $5.52M (+$1.97M)
0.7% more ownership
Funds ownership: 28.55% → 29.25% (+0.7%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
4% less funds holding
Funds holding: 46 → 44 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$88.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.2K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$12.1K |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
+$9.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$24.6K |
| 2 |
JGC
J. Goldman & Co
New York
|
-$14.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$12.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.72K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.31K |
TXMD Hedge Fund Activity: Q4 2025 in Review
44 of the 8,271 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2025, worth a combined $5.52M — up 56% from $3.54M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TXMD and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $88.2K. The largest seller was Bridgeway Capital Management, cutting an estimated $24.6K.
- 44 institutional investors held TherapeuticsMD (TXMD) as of Q4 2025, down from 46 in Q3 2025.
- Funds reported $5.52M of TherapeuticsMD stock for Q4 2025, up 56% quarter-over-quarter.
- 4 funds opened new TherapeuticsMD positions in Q4 2025 and 6 closed out, a net change of -2 holders.
- The largest TherapeuticsMD buyer in Q4 2025 was Renaissance Technologies, an estimated $88.2K added.
- The largest TherapeuticsMD seller in Q4 2025 was Bridgeway Capital Management, an estimated $24.6K sold.
Based on aggregated 13F filings for Q4 2025.